DRUG SUPPLIED DOSE COMMENTS
BREVICON (Paeds)
(ethinyl estradiol and norethindrone)

Mechanism of action:

Hormone; Oral contraceptive


Ref: 143, 153, 413, 658, 661



Last update: 2022-06-08		 tablet: 35 mcg ethinyl estradiol and 1 mg norethindrone Prevention of menstrual bleeds in post-menarchal patients:
one tablet PO daily (continuous)

Acute abnormal uterine bleeding: (including break-through bleeding with leuprolide in oncology patients):
1 tablet TID-QID until cessation of bleeding then taper as tolerated to maintain control of bleeding

Contains higher estrogen content than other oral contraceptives.

Consider concurrent administration of an anti-emetic.

Not recommended if receiving bone marrow or stem cell transplant due to risk of hyperbilirubinemia and hepatic veno-occlusive disease.

May be safely administered with short courses (2-5 days) of tranexamic acid.

May be used for emergency contraception if levonorgestrel (Plan B) is unavailable. Levonorgestrel preferred due to effectiveness and safety profile.


Standard Prescription:

Prevention of menstruation:
Brevicon 1 tablet PO daily

Acute abnormal uterine bleed:
Brevicon 1 tablet PO__(frequency) x __ days